Episode #105 | Jan 2026 News: ARPA-H Organ "Moonshots", Point-of-Care Manufacturing, and More
Mon Jan 26 2026
We track a month of fast-moving news in healthcare 3D printing, from organ-scale bioprinting programs and ARPA-H’s funding model to point-of-care tools already entering clinics. The throughline is clear: vascularization, immune compatibility, and scale are converging with real-world deployment.
• UT Southwestern’s organoid-plus-bioprinting strategy for durable liver tissue
• Carnegie Mellon’s consortium on vascularization, immune control, and scale
• ARPA-H’s moonshot funding model is accelerating medical innovation
• Aspect Biosystems and Novo Nordisk’s bet on curing diabetes
• Cost shift from chronic management to curative therapies
• Near-term point-of-care printing: Curify Labs and AZORG integrations
• Key milestone to watch: functional vascular networks
• Outlook as research, industry, and funding align
Remember, this podcast is for educational and informational purposes only
The views expressed do not constitute engineering, medical, or financial advice. The technologies and procedures discussed may not be commercially available or suitable for every case. Always consult with a qualified professional
Shownotes: https://3dheals.com/lattice-news-arpa-h-organ-moonshots-point-of-care-manufacturing-and-more/
Send us a text
Support the show
Subscribe to our premium version and support the show.
Follow us:
Twitter
Instagram
Linkedin
3DHEALS Website
Facebook
Facebook Group
Youtube channel
About Pitch3D
More
We track a month of fast-moving news in healthcare 3D printing, from organ-scale bioprinting programs and ARPA-H’s funding model to point-of-care tools already entering clinics. The throughline is clear: vascularization, immune compatibility, and scale are converging with real-world deployment. • UT Southwestern’s organoid-plus-bioprinting strategy for durable liver tissue • Carnegie Mellon’s consortium on vascularization, immune control, and scale • ARPA-H’s moonshot funding model is accelerating medical innovation • Aspect Biosystems and Novo Nordisk’s bet on curing diabetes • Cost shift from chronic management to curative therapies • Near-term point-of-care printing: Curify Labs and AZORG integrations • Key milestone to watch: functional vascular networks • Outlook as research, industry, and funding align Remember, this podcast is for educational and informational purposes only The views expressed do not constitute engineering, medical, or financial advice. The technologies and procedures discussed may not be commercially available or suitable for every case. Always consult with a qualified professional Shownotes: https://3dheals.com/lattice-news-arpa-h-organ-moonshots-point-of-care-manufacturing-and-more/ Send us a text Support the show Subscribe to our premium version and support the show. Follow us: Twitter Instagram Linkedin 3DHEALS Website Facebook Facebook Group Youtube channel About Pitch3D